Riboxin

Riboxin is an anabolic drug with antihypoxic and antiarrhythmic effects.

Indications Riboxin

Complex treatment of ischemic heart disease (condition after myocardial infarction, angina pectoris), heart rhythm disorders, intoxication with cardiac glycosides, treatment of cardiomyopathies of various genesis, myocardiodystrophy (against the background of heavy physical exertion, infectious and endocrine genesis), myocarditis; liver diseases (hepatitis, cirrhosis, fatty liver dystrophy); urokoproporphyria.

Release form

Coated tablets.

Basic physicochemical properties: yellow-colored, coated tablets with biconvex surface. Two layers are visible on the cross section.

Pharmacodynamics

It is a precursor of ATP, directly participates in glucose metabolism and contributes to the activation of metabolism under hypoxia and in the absence of ATP. The drug activates pyruvic acid metabolism to ensure the normal process of tissue respiration, and also contributes to the activation of xanthine dehydrogenase. Riboxin has a positive effect on myocardial metabolism, in particular, increases the energy balance of cells, stimulates the synthesis of nucleotides, increases the activity of a number of enzymes of the Krebs cycle. The drug normalizes contractile activity of myocardium and promotes more complete relaxation of myocardium in diastole due to the ability to bind calcium ions that entered the cells during excitation, activates tissue regeneration (especially myocardium and gastrointestinal mucosa).

Pharmacokinetics

Well absorbed in the gastrointestinal tract. Metabolized in the liver with formation of glucuronic acid and its further oxidation. Excreted mainly with urine, in insignificant amounts - with feces and bile.

Dosing and administration

The drug is administered orally before meals, do not chew, drink enough water. The daily dose for adults is established by a doctor individually, the dose is 600-2400 mg per day. At the beginning of treatment usually the drug should be prescribed in a daily dose of 600-800 mg (1 tablet 3-4 times a day). If the drug is well tolerated, the dose is gradually increased (within 2-3 days) up to 1200 mg per day (2 tablets 3 times per day), if necessary - up to 2400 mg per day (4 tablets 3 times per day). Duration of the course of treatment - 1-3 months.

In urocoproporphyria the daily dose is 800 mg (1 tablet 4 times a day), duration of treatment - 1-3 months.

Kids.

The medicine should not be used in children due to the lack of data on the safety of use.

Use Riboxin during pregnancy

The study of efficacy and safety of the medicinal product for this group of patients has not been conducted, therefore the medicinal product should not be used during pregnancy or lactation.

Ability to affect the speed of reactions when driving motor transport or other mechanisms.

The drug does not affect the rate of neuromuscular conduction, in the recommended doses it can be used by persons driving motor vehicles and working with complex mechanisms.

Contraindications

Hypersensitivity to the active substance or to other components of the medicinal product; gout; hyperuricemia. Renal insufficiency is a restriction to the use of the medicinal product.

Side effects Riboxin

Metabolism: hyperuricemia, exacerbation of gout (with prolonged use of high doses).

Cardiovascular system: tachycardia, arterial hypotension, may be accompanied by headache, dyspnea, dizziness, nausea, vomiting, sweating.

Immune system: allergic/anaphylactic reactions, including rash, pruritus, skin hyperemia, urticaria, anaphylactic shock.

General disorders: general weakness.

Laboratory values: increased uric acid levels in the blood.

If any adverse reactions occur, discontinue use of the medicinal product.

Overdose

No cases of overdose of the medicinal product have been reported. If the dose of the medicinal product is exceeded, side effects may increase.

Treatment: withdrawal of the drug, symptomatic therapy.

Interactions with other drugs

Co-administration of the drug with other medicines is possible:

• with heparin - enhancing the effects of heparin, increasing the duration of its action;
• with cardiac glycosides - prevention of arrhythmias, enhancement of positive inotropic action;
• with hypouricemic agents - weakening of the effects of hypouricemic agents.

In concomitant use of the drug with β-adrenoblockers, the effect of riboxin is not reduced.

Concomitant use with nitroglycerin, nifedipine, furosemide, spironolactone is possible.

Special instructions

Riboxin should not be used for emergency correction of cardiac disorders.

In case of itching and hyperemia of the skin, treatment with the drug should be canceled.

During treatment it is necessary to monitor the level of uric acid concentration in blood and urine.

Renal insufficiency is a restriction for use of the medicinal product. In renal insufficiency it is advisable to prescribe the medicinal product only when, in the opinion of the physician, the expected effect of use exceeds the possible risk.

The medicine contains crystalline sugar, which should be taken into account by diabetics.